Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study

September 13, 2026 7:00 AM EDT

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab

HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months

PD-L1 High Expression Subgroup: Hazard Ratio = 0.58

Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc.... More